In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1284-1290

  Aviles, Pablo ^a   Aliouat, El Moukhtar ^a,b   Martinez, Antonio ^a   Dei Cas, Eduardo ^c,d   Herreros, Esperanza ^a   Dujardin, Lucien ^d   Gargallo Viola, Domingo ^a  

^a GLAXOSMITHKLINE   (Spain)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; COTRIMOXAZOLE; DEXAMETHASONE; DIMETHYL SULFOXIDE; GM 191519; GM 193663; GM 219771; GM 237354; PENTAMIDINE; SORDARIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GIEMSA STAIN; NONHUMAN; PARASITE ISOLATION; PHARMACODYNAMICS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INDENES; MICROBIAL SENSITIVITY TESTS; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, WISTAR;

EID: 0034007452     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1284-1290.2000     Document Type: Article

References (30)

1. Acred, P., T. D. Hennessey, J. A. MacArthur-Clark, D. J. Merrikin, D. M. Ryan, H. C. Smulders, P. F. Troke, R. G. Wilson, and D. W. Straughan. 1994. Guidelines for the welfare of animals in rodent protection tests. A report from the rodent test working party. Lab. Anim. 28:13-18.
2. Aliouat, E. M., A. Martinez, E. Jimenez, E. Dei-Cas, C. Mullet, P. Delcourt, and D. Gargallo-Viola. 1997. Development of Pneumocystis animal models: corticosteroid-treated Wistar rat; SCID mouse and Nude rat. J. Eukaryot. Microbiol. 44:41S-42S.
3. Aliouat, E. M., E. Dei-Cas, M. A. Ouassi, F. Palluault, B. Soulez, and D. Camus. 1993. In vitro attachment of Pneumocystis carinii from mouse and rat origin. Biol. Cell 77:209-217.
4. Aliouat, E. M., E. Mazars, E. Dei-Cas, J. Y. Cesbron, and D. Camus. 1993. Intranasal inoculation of mouse, rat or rabbit-derived Pneumocystis in SCID mouse. J. Protozool. Res. 3:94-98.
5. Aliouat, E. M., L. Dujardin, A. Martinez, T. Duriez, and E. Dei-Cas. 1999. Pneumocystis carinii growth kinetics in culture systems and in hosts: involvement of each life cycle parasite stage. J. Eukaryot. Microbiol. 46:116S-117S.
6. Amsterdam, D. 1991. Susceptibility testing of antimicrobials in liquid media, p. 53-105. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins, Ltd., Baltimore, Md.
7. Barlett, M. S. 1991. Models for evaluating compounds for activity against Pneumocystis carinii. Eur. J. Clin. Microbiol. Infect. Dis. 10:199-201.
8. Cirioni, O., A. Giacometti, and G. Scalise. 1997. In vitro activity of atovaquone, sulfamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. J. Antimicrob. Chemother. 39:45-51.
9. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins, Ltd., Baltimore, Md.
10. Cushion, M. T. 1989. In vitro studies of Pneumocystis carinii. J. Protozool. 36:45-52.
11. Dominguez, J. M., V. A. Kelly, O. S. Kinsman, M. S. Marriott, F. Gomez de las Heras, and J. J. Martin. 1998. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. 42:2274-2278.
12. Drusano, G. L. 1988. Role of pharmacokinetics in the outcome of infections. Antimicrob. Agents Chemother. 32:289-297.
13. Herreros, E., C. M. Martinez, M. J. Almela, M. S. Marriott, F. Gomez de las Heras, and D. Gargallo-Viola. 1998. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob. Agents Chemother. 42:2863-2869.
14. Herreros, E., M. J. Almela, C. M. Martinez, S. Lozano, H. Jackson, E. M. Aliouat, and D. Gargallo-Viola. 1997. Microplate assays for In vitro evaluation of anti-pneumocystis drugs. J. Eukaryot. Microbiol. 44:43S-44S.
15. Merali, S., and S. R. Meshnick. 1991. Susceptibility of Pneumocystis carinii to artemisinin in vitro. Antimicrob. Agents Chemother. 35:1225-1227.
16. Merali, S., U. Frevert, J. H. Williams, K. Chin, R. Bryan, and A. B. Clarkson, Jr. 1999. Continuous axenic cultivation of Pneumocystis carinii. Proc. Natl. Acad. Sci. USA 96:2402-2407.
17. Mouton, J. W., A. A. T. M. M. Vinks, and N. C. Punt. 1997. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738.
18. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved standard M7-A2 10. National Committee for Clinical Laboratory Standards, Villanova, Pa.
19. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. National Committee for Clinical Laboratory Standards. 1999. Methodology for the serum bactericidal test. Approved guideline M21-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
22. Oz, H. S., and W. T. Hughes. 1996. Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii. Lab. Anim. Sci. 46:109-110.
23. Pifer, L. L., D. D. Pifer, and D. R. Woods. 1983. Biological profile and response to anti-Pneumocystis agents of Pneumocystis carinii in cell culture. Antimicrob. Agents Chemother. 24:673-678.
24. Schmatz, D. M., M. Powles, D. C. McFadden, L. A. Pittarelli, P. A. Liberator, and J. W. Anderson. 1991. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J. Protozool. 38:151S-153S.
25. Sloand, E., B. Laughon, M. Armstrong, M. S. Bartlett, W. Blumenfeld, M. T. Cushion, A. Kalica, J. A. Kovacs, W. Martin, E. Pitt, E. L. Pesanti, F. Richards, R. Rose, and P. Walzer. 1993. The challenge of Pneumocystis carinii culture. J. Eukaryot. Microbiol. 40:188-195.
26. Smith, J. W., M. S. Bartlett, and S. F. Queener. 1994. Development of models and their use to discover new drugs for therapy and prophylaxis of Pneumocystis carinii pneumonia. In P. D. Walzer (ed.), Pneumocystis carinii pneumonia. Marcell Decker, Inc., New York, N.Y.
27. Soulez, B., E. Dei-Cas, and D. Camus. 1988. Le lapin, hôte experimental de Pneumocystis carinii. Ann. Parasitol. Hum. Comp. 63:5-15.
28. Soulez, B., E. Dei-Cas, F. Palluault, and D. Camus. 1991. Morphological evaluation of Pneumocystis carinii after extraction from infected lung. J. Parasitol. 77:449-453.
29. Stringer, J. R. 1996. Pneumocystis carinii: what is it, exactly? Clin. Microbiol. Rev. 9:489-498.
30. Whiting, B., and A. G. Gilman. 1980. The modeling of drug response. Clin. Sci. 59:311-315.